Skip to main content
OpenTrials
Completed

NCT Number: NCT01229059

Free Fatty Acid Induced Insulin Resistance

This study aims to explore time-dependent effects of lipid infusion an intramyocellular lipid metabolites and the induction of impaired insulin signaling.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

German Diabetes Center

Düsseldorf, North Rhine-Westphalia, 40225, Germany

About this study

Increased availability of free fatty acids impairs glucose disposal in young healthy humans. Patients with type 2 diabetes have reduced whole body glucose disposal, increased ectopic lipid deposition in skeletal muscle and the liver and impaired mitochondrial function. Recent studies suggest that lipid metabolites such as diacylglycerol (DAG), ceramides and long-chain acyl-coA represent the active mediators inducing insulin resistance. Possible targets are DAG-sensitive Proteinkinase C (PKC θ, PKC ε) which inhibit the insulin signaling cascade and ceramides which interfere with the insulin signaling cascade at Proteinkinase B/AKT. Prior studies raised controvesial evidence, thus, it is yet unclear, whether DAG or ceramides are the primary agents inducig lipid-induced insulin resistance. Therefore, the current study aims to explore the time course of the appearance of intramyocellular lipid compunds during lipid infusion in parallel assessing markers of impaired insulin action.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • non-diabetic (OGTT), no family history of diabetes, BMI<30 kg/m2, age: 20-55 years, no medication

For the athletes group additionally:

  • VO2max > 60ml/kg/min for males and VO2max > 45ml/kg/min for females Active in endurance-exercise activities, 3 times a week for at least 2 years Stable level of training for at least 3 months

Exclusion criteria

  • acute illness within the last 2 weeks, autoimmune diseases, renal insufficiency (creatinine> 1.5 mg/dl), cardiovascular diseases, anemia (Hb< 12g/l), donation of blood within the last 4 weeks before the study, thyroid diseases, pregnancy, smoking, night-shift working (disturbed circadian rhythm), defective coagulation or wound healing, cancer, allergy against soja products

Treatment and study plan

Lipovenös lipid infusion

Dietary Supplement

Lipid enriched infusions will be applied for 2-6 hours.

Other names: soy oil

Primary outcomes

  1. intramyocellular lipid metabolites

    Time frame: after 4 hours lipid infusion

    Muscle biopsies are taken before, after 2.5 and 4 hours of lipid infusion

  2. muscle glucose flux

    Time frame: during lipid infusion

    glycogen synthesis rate, glucose-6-phosphate

Secondary outcomes

  1. insulin resistance of glucose uptake and mitochondrial function

    Time frame: after 4 hours lipid infusion

    Mitochondrial function will bes assessed from muscle biopsy samples taken after 4 hours, insulin sensitivity will be assessed from hyperinsulinemic-euglycemic clamps following 4 hours lipid infusion

Sponsors and collaborators

Lead sponsor

German Diabetes Center

Other

Collaborators

  • Heinrich-Heine University, Duesseldorf

Registry information

Official study title

Assessment of the Time Course of Lipid Induced Insulin Resistance

Acronym: FFAIR

Important dates

Study start
2010
Primary completion
2019
Study completion
2019
First posted
Oct 27, 2010
Registry last updated
Aug 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.